Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | BLK | P51451 | 1/20 | 0.44 |
| ▸ | BMX | P51813 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1040621 | 0.81 | EGFR (0.61) | EGFRCTSCMAPT | |
| SCHEMBL16334422 | 0.78 | DHFR (0.55) | DHFRNPC1MAPT | |
| SCHEMBL2599592 | 0.77 | ADRA2C (0.49) | EGFRADRA2CCTSCBRD4HRH4 | |
| SCHEMBL3656991 | 0.75 | ADRA2C (0.47) | EGFRADRA2CCTSCBRD4HRH4 | |
| SCHEMBL1036727 | 0.75 | KMT2A (0.50) | EGFRBRD4MAPT | |
| SCHEMBL30127171 | 0.74 | SMN1; SMN2 (0.56) | NPC1MAPT | |
| SCHEMBL27894494 | 0.74 | ALDH1A1 (0.37) | EGFRCTSCBRD4JAK2BLK | |
| SCHEMBL1041059 | 0.74 | CASP6 (0.53) | EGFRMAPT | |
| SCHEMBL1706688 | 0.73 | EGFR (1.00) | EGFRCTSCJAK2BLKBMX | |
| Ammonia Solution, Strong SCHEMBL1039812 | 0.73 | CASP6 (0.52) | EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349862-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL HEALTHCARE LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| CN-101547902-B | pyridine derivatives for treatment of metabolic disorders related with insulin resistance and hyperglycemia | PIRAMAL LIFE SCIENCES LTD | 2012-10-31 | — | — | CN | disclosed |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-12-22 | — | — | US | disclosed |
| US-8030324-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-10-04 | — | — | US | disclosed |
| EP-2094663-B1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-01-26 | — | — | EP | disclosed |
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Enterprises Limited (IN) | 2010-01-28 | — | — | US | disclosed |
| EP-2094663-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008035305-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | EGFR 2614/4885ADRA2C 1065/4885CTSC 935/4885 |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | EGFR 2614/4885ADRA2C 1065/4885CTSC 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.